(202 days)
The ULTRAMIST 2000 is an aerosol therapy apparatus which is designed for the treatment of respiratory disorders. It is designed for home use by patients ranging in age from toddlers to adult to geriatric. Normal usage is based on prescribed medication and is typically used three to four times a day.
Through the use of a separate nebulizer, it produces a simple means for delivering medication in a mist form which is inhaled into the bronchial tree for therapeutic reasons. A treatment of 3 - 3.5 ml can be completed in less than 10 minutes and produces microscopic particles which allow for deeper penetration.
The device is to be used only on the order of a licensed physician.
The ULTRAMIST 2000 is an aerosol therapy apparatus.
The provided text is a 510(k) premarket notification letter from the FDA regarding the Ultramist 2000 device. It confirms that the device is substantially equivalent to legally marketed predicate devices.
However, the provided document does not contain any information about acceptance criteria, device performance metrics, study details (like sample size, data provenance, expert qualifications, adjudication methods), or any comparative effectiveness studies (MRMC, standalone performance). It also does not mention how the ground truth was established for training or testing sets.
Therefore, I cannot provide the requested information based on the input document. The document primarily focuses on the regulatory approval process and the intended use of the device as an aerosol therapy apparatus for respiratory disorders.
§ 868.5630 Nebulizer.
(a)
Identification. A nebulizer is a device intended to spray liquids in aerosol form into gases that are delivered directly to the patient for breathing. Heated, ultrasonic, gas, venturi, and refillable nebulizers are included in this generic type of device.(b)
Classification. Class II (performance standards).